The Acquirers Podcast Andrew Summers of Summers Value Partners on healthcare, biotech $GILD, $QURE and $ELMD | S08 E02
28 snips
Jan 22, 2026 Andrew Summers, founder of Summers Value Fund, shares insights from his extensive experience in healthcare and biotech investing. He discusses regulatory complexities impacting the sector, recent underperformance, and the attractiveness of biotech as it matures. Summers highlights the dramatic patent cliffs ahead for large pharmaceutical companies and the role of innovative treatments like GLP-1s. He also explores how technologies like AI are reshaping drug development and why small-cap healthcare offers compelling opportunities.
AI Snips
Chapters
Transcript
Episode notes
Patent Cliff Will Fuel M&A
- Biotech moves in innovation waves and M&A often follows patent cliffs.
- Summers expects a multi-year M&A cycle because major pharma face an unprecedented patent-expiry wave through 2030.
GLP-1s Are Transformative
- GLP-1s are arguably the closest thing to a 'magic pill' with broad metabolic and cardiovascular benefits.
- Their impact spans weight, lipids, blood pressure and potentially cancer and cognitive disease outcomes.
Early Bet On Oral Wegovy
- Summers recounts early work on oral Wegovy and securing a royalty on the oral form.
- He sold that asset to Novo Nordisk in 2020 and later reflected it was sold too cheaply.